SCHEMBL3054334

SCHEMBL3054334

O=C(Cc1cccs1)OCc1cccc2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.65
▸ KMT2A Q03164 5/20 0.65
▸ SMN1; SMN2 Q16637 4/20 0.65
▸ ALDH1A1 P00352 4/20 0.65
▸ POLB P06746 3/20 0.65
▸ LMNA P02545 3/20 0.65
▸ HPGD P15428 3/20 0.65
▸ L3MBTL1 Q9Y468 2/20 0.65
▸ BLM P54132 1/20 0.65
▸ MAPT P10636 4/20 0.47
▸ THRB P10828 1/20 0.47
▸ SLC1A3 P43003 1/20 0.47
▸ SLC1A2 P43004 1/20 0.47
▸ SLC1A1 P43005 1/20 0.47
▸ TDP1 Q9NUW8 2/20 0.46
▸ NR2F2 P24468 1/20 0.46
▸ RAB9A P51151 1/20 0.45
▸ EPHX1 P07099 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3053077 0.89 L3MBTL1 (0.61) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL23094223 0.79 L3MBTL1 (1.00) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL6970386 0.77 ALDH1A1 (0.64) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL8400366 0.75 EPHX1 (0.51) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL23932603 0.75 MEN1 (0.52) MEN1KMT2AALDH1A1L3MBTL1SLC1A3
Cyclopropane SCHEMBL11350996 0.75 MAPT (0.58) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL28702056 0.74 TDP1 (0.56) MEN1KMT2AL3MBTL1SLC1A3SLC1A2
SCHEMBL21372579 0.74 TDP1 (0.56) MEN1KMT2AL3MBTL1SLC1A3SLC1A2
SCHEMBL6677814 0.74 CDYL (0.63) MEN1KMT2ASLC1A3SLC1A2SLC1A1
SCHEMBL3041845 0.74 HPGD (0.53) MEN1KMT2ASMN1; SMN2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8647878-B2 Highly refractive immersion liquids and their use CARL ZEISS AG (DE) 2014-02-11 — — US disclosed
US-8647878-B2 Highly refractive immersion liquids and their use CARL ZEISS AG (DE) 2014-02-11 — — US disclosed
US-8647878-B2 Highly refractive immersion liquids and their use CARL ZEISS AG (DE) 2014-02-11 — — US disclosed
US-20100212547-A1 Highly Refractive Immersion Liquids And Their Use CARL ZEISS AG (DE) 2010-08-26 — — US disclosed
US-20100212547-A1 Highly Refractive Immersion Liquids And Their Use CARL ZEISS AG (DE) 2010-08-26 — — US disclosed
US-20100212547-A1 Highly Refractive Immersion Liquids And Their Use CARL ZEISS AG (DE) 2010-08-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100212547-A1 Highly Refractive Immersion Liquids And Their Use NR4A3, NR2E3, NR4A1 MEN1 2974/4885KMT2A 3367/4885SMN1; SMN2 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback